These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 36807080)

  • 21. Long term effect of delayed treatment on disability in patients with paediatric onset multiple sclerosis: A prospective Danish cohort study.
    Kopp TI; Blinkenberg M; Petersen T; Sorensen PS; Magyari M
    Mult Scler Relat Disord; 2020 May; 40():101956. PubMed ID: 32007654
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Information processing speed as a prognostic marker of physical impairment and progression in patients with multiple sclerosis.
    Hechenberger S; Helmlinger B; Ropele S; Pirpamer L; Bachmaier G; Damulina A; Pichler A; Khalil M; Enzinger C; Pinter D
    Mult Scler Relat Disord; 2022 Jan; 57():103353. PubMed ID: 35158430
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Thalamic Nuclei Volumes and Their Relationships to Neuroperformance in Multiple Sclerosis: A Cross-Sectional Structural MRI Study.
    Bergsland N; Benedict RHB; Dwyer MG; Fuchs TA; Jakimovski D; Schweser F; Tavazzi E; Weinstock-Guttman B; Zivadinov R
    J Magn Reson Imaging; 2021 Mar; 53(3):731-739. PubMed ID: 33044013
    [TBL] [Abstract][Full Text] [Related]  

  • 24. MRI brain volume loss, lesion burden, and clinical outcome in secondary progressive multiple sclerosis.
    Koch MW; Mostert J; Repovic P; Bowen JD; Strijbis E; Uitdehaag B; Cutter G
    Mult Scler; 2022 Apr; 28(4):561-572. PubMed ID: 34304609
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Binocular low-contrast letter acuity and the symbol digit modalities test improve the ability of the Multiple Sclerosis Functional Composite to predict disease in pediatric multiple sclerosis.
    Waldman AT; Chahin S; Lavery AM; Liu G; Banwell BL; Liu GT; Balcer LJ
    Mult Scler Relat Disord; 2016 Nov; 10():73-78. PubMed ID: 27919503
    [TBL] [Abstract][Full Text] [Related]  

  • 26. An enrichment strategy for clinical trials in SPMS.
    Koch MW; Metz L; Cutter G
    Mult Scler; 2021 Oct; 27(12):1884-1893. PubMed ID: 33404355
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Discontinuation of disease modifying therapies is associated with disability progression regardless of prior stable disease and age.
    Jakimovski D; Kavak KS; Vaughn CB; Goodman AD; Coyle PK; Krupp L; Gottesman M; Edwards KR; Lenihan M; Perel A; Zivadinov R; Weinstock-Guttman B;
    Mult Scler Relat Disord; 2022 Jan; 57():103406. PubMed ID: 34915316
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension.
    Kapoor R; Ho PR; Campbell N; Chang I; Deykin A; Forrestal F; Lucas N; Yu B; Arnold DL; Freedman MS; Goldman MD; Hartung HP; Havrdová EK; Jeffery D; Miller A; Sellebjerg F; Cadavid D; Mikol D; Steiner D;
    Lancet Neurol; 2018 May; 17(5):405-415. PubMed ID: 29545067
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A Deep Learning Approach to Predicting Disease Progression in Multiple Sclerosis Using Magnetic Resonance Imaging.
    Storelli L; Azzimonti M; Gueye M; Vizzino C; Preziosa P; Tedeschi G; De Stefano N; Pantano P; Filippi M; Rocca MA
    Invest Radiol; 2022 Jul; 57(7):423-432. PubMed ID: 35093968
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Risk of Persistent Disability in Patients With Pediatric-Onset Multiple Sclerosis.
    Baroncini D; Simone M; Iaffaldano P; Brescia Morra V; Lanzillo R; Filippi M; Romeo M; Patti F; Chisari CG; Cocco E; Fenu G; Salemi G; Ragonese P; Inglese M; Cellerino M; Margari L; Comi G; Zaffaroni M; Ghezzi A;
    JAMA Neurol; 2021 Jun; 78(6):726-735. PubMed ID: 33938921
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The clinical and paraclinical correlates of employment status in multiple sclerosis.
    Srpova B; Sobisek L; Novotna K; Uher T; Friedova L; Vaneckova M; Krasensky J; Kubala Havrdova E; Horakova D
    Neurol Sci; 2022 Mar; 43(3):1911-1920. PubMed ID: 34392392
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Slowly Expanding Lesions Predict 9-Year Multiple Sclerosis Disease Progression.
    Preziosa P; Pagani E; Meani A; Moiola L; Rodegher M; Filippi M; Rocca MA
    Neurol Neuroimmunol Neuroinflamm; 2022 Mar; 9(2):. PubMed ID: 35105685
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Working ability in individuals with different disease courses of multiple sclerosis: Factors beyond physical impairment.
    Renner A; Baetge SJ; Filser M; Penner IK
    Mult Scler Relat Disord; 2020 Nov; 46():102559. PubMed ID: 33035965
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Predicting disability progression and cognitive worsening in multiple sclerosis using patterns of grey matter volumes.
    Colato E; Stutters J; Tur C; Narayanan S; Arnold DL; Gandini Wheeler-Kingshott CAM; Barkhof F; Ciccarelli O; Chard DT; Eshaghi A
    J Neurol Neurosurg Psychiatry; 2021 Sep; 92(9):995-1006. PubMed ID: 33879535
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Slowly expanding lesions relate to persisting black-holes and clinical outcomes in relapse-onset multiple sclerosis.
    Calvi A; Tur C; Chard D; Stutters J; Ciccarelli O; Cortese R; Battaglini M; Pietroboni A; De Riz M; Galimberti D; Scarpini E; De Stefano N; Prados F; Barkhof F
    Neuroimage Clin; 2022; 35():103048. PubMed ID: 35598462
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Disability measurement in Multiple Sclerosis patients 55 years and older: What is the Expanded Disability Status Scale really telling clinicians?
    Lynch S; Baker S; Nashatizadeh M; Thuringer A; Thelen J; Bruce J
    Mult Scler Relat Disord; 2021 Apr; 49():102724. PubMed ID: 33609959
    [TBL] [Abstract][Full Text] [Related]  

  • 37. How patients with multiple sclerosis acquire disability.
    Lublin FD; Häring DA; Ganjgahi H; Ocampo A; Hatami F; Čuklina J; Aarden P; Dahlke F; Arnold DL; Wiendl H; Chitnis T; Nichols TE; Kieseier BC; Bermel RA
    Brain; 2022 Sep; 145(9):3147-3161. PubMed ID: 35104840
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The role of disability and depression in cognitive functioning within 2 years after multiple sclerosis diagnosis.
    Siepman TA; Janssens AC; de Koning I; Polman CH; Boringa JB; Hintzen RQ
    J Neurol; 2008 Jun; 255(6):910-6. PubMed ID: 18484237
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Associations of Disease-Modifying Therapies With COVID-19 Severity in Multiple Sclerosis.
    Simpson-Yap S; De Brouwer E; Kalincik T; Rijke N; Hillert JA; Walton C; Edan G; Moreau Y; Spelman T; Geys L; Parciak T; Gautrais C; Lazovski N; Pirmani A; Ardeshirdavanai A; Forsberg L; Glaser A; McBurney R; Schmidt H; Bergmann AB; Braune S; Stahmann A; Middleton R; Salter A; Fox RJ; van der Walt A; Butzkueven H; Alroughani R; Ozakbas S; Rojas JI; van der Mei I; Nag N; Ivanov R; Sciascia do Olival G; Dias AE; Magyari M; Brum D; Mendes MF; Alonso RN; Nicholas RS; Bauer J; Chertcoff AS; Zabalza A; Arrambide G; Fidao A; Comi G; Peeters L
    Neurology; 2021 Nov; 97(19):e1870-e1885. PubMed ID: 34610987
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The timed 25-foot walk is a more sensitive outcome measure than the EDSS for PPMS trials: an analysis of the PROMISE clinical trial dataset.
    Koch MW; Mostert J; Repovic P; Bowen JD; Comtois J; Strijbis E; Uitdehaag B; Cutter G
    J Neurol; 2022 Oct; 269(10):5319-5327. PubMed ID: 35570237
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.